Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

ApiAP2 Transcription Factors in Apicomplexan Parasites.

Jeninga MD, Quinn JE, Petter M.

Pathogens. 2019 Apr 7;8(2). pii: E47. doi: 10.3390/pathogens8020047. Review.

2.

BRCA1 and MAD2 Are Coexpressed and Are Prognostic Indicators in Tubo-ovarian High-Grade Serous Carcinoma.

Byrne T, Nelson L, Beirne JP, Sharpe D, Quinn JE, McCluggage WG, Robson T, Furlong F.

Int J Gynecol Cancer. 2018 Mar;28(3):472-478. doi: 10.1097/IGC.0000000000001214.

PMID:
30814209
3.

Active and Passive Use of Green Space, Health, and Well-Being amongst University Students.

Holt EW, Lombard QK, Best N, Smiley-Smith S, Quinn JE.

Int J Environ Res Public Health. 2019 Feb 1;16(3). pii: E424. doi: 10.3390/ijerph16030424.

4.

BRCA1 and MAD2 Are Coexpressed and Are Prognostic Indicators in Tubo-ovarian High-Grade Serous Carcinoma.

Byrne T, Nelson L, Beirne JP, Sharpe D, Quinn JE, McCluggage WG, Robson T, Furlong F.

Int J Gynecol Cancer. 2018 Mar;28(3):472-478. doi: 10.1097/IGC.0000000000001214.

PMID:
29465507
5.

Digging Deeper: A Case Study of Farmer Conceptualization of Ecosystem Services in the American South.

Quinn CE, Quinn JE, Halfacre AC.

Environ Manage. 2015 Oct;56(4):802-13. doi: 10.1007/s00267-015-0534-9. Epub 2015 May 16.

PMID:
25982618
6.

Computer-based cognitive rehabilitation research in a military treatment facility: Recruitment, compliance, and lessons learned.

Sullivan KW, Solomon NP, Pramuka M, Quinn JE, Teixeira KA, French LM.

Work. 2015;50(1):131-42. doi: 10.3233/WOR-141986.

PMID:
25515174
7.

Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer.

Mulligan JM, Hill LA, Deharo S, Irwin G, Boyle D, Keating KE, Raji OY, McDyer FA, O'Brien E, Bylesjo M, Quinn JE, Lindor NM, Mullan PB, James CR, Walker SM, Kerr P, James J, Davison TS, Proutski V, Salto-Tellez M, Johnston PG, Couch FJ, Paul Harkin D, Kennedy RD.

J Natl Cancer Inst. 2014 Jan;106(1):djt335. doi: 10.1093/jnci/djt335.

8.

BRCA1 is a key regulator of breast differentiation through activation of Notch signalling with implications for anti-endocrine treatment of breast cancers.

Buckley NE, Nic An tSaoir CB, Blayney JK, Oram LC, Crawford NT, D'Costa ZC, Quinn JE, Kennedy RD, Harkin DP, Mullan PB.

Nucleic Acids Res. 2013 Oct;41(18):8601-14. doi: 10.1093/nar/gkt626. Epub 2013 Jul 17.

9.

BRCA1 immunohistochemical staining as a prognostic indicator in uterine serous carcinoma.

Beirne JP, Quinn JE, Maxwell P, Kalloger SE, McAlpine J, Gilks CB, Harley IJ, McCluggage WG.

Int J Gynecol Cancer. 2013 Jan;23(1):113-8. doi: 10.1097/IGC.0b013e3182798188.

PMID:
23221734
10.

Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival.

Mukhopadhyay A, Plummer ER, Elattar A, Soohoo S, Uzir B, Quinn JE, McCluggage WG, Maxwell P, Aneke H, Curtin NJ, Edmondson RJ.

Cancer Res. 2012 Nov 15;72(22):5675-82. doi: 10.1158/0008-5472.CAN-12-0324. Epub 2012 Oct 11.

11.

Outcomes from a pilot study using computer-based rehabilitative tools in a military population.

Sullivan KW, Quinn JE, Pramuka M, Sharkey LA, French LM.

Stud Health Technol Inform. 2012;181:71-7.

PMID:
22954831
12.

BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma.

Busacca S, Sheaff M, Arthur K, Gray SG, O'Byrne KJ, Richard DJ, Soltermann A, Opitz I, Pass H, Harkin DP, Quinn JE, Fennell DA.

J Pathol. 2012 Jun;227(2):200-8. doi: 10.1002/path.3979. Epub 2012 Mar 19.

PMID:
22190288
13.

BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer.

Carser JE, Quinn JE, Michie CO, O'Brien EJ, McCluggage WG, Maxwell P, Lamers E, Lioe TF, Williams AR, Kennedy RD, Gourley C, Harkin DP.

Gynecol Oncol. 2011 Dec;123(3):492-8. doi: 10.1016/j.ygyno.2011.08.017. Epub 2011 Sep 13.

PMID:
21920589
14.

PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.

Paul I, Savage KI, Blayney JK, Lamers E, Gately K, Kerr K, Sheaff M, Arthur K, Richard DJ, Hamilton PW, James JA, O'Byrne KJ, Harkin DP, Quinn JE, Fennell DA.

J Pathol. 2011 Aug;224(4):564-74. doi: 10.1002/path.2925. Epub 2011 Jun 27.

PMID:
21706479
15.

BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer.

Gorski JJ, James CR, Quinn JE, Stewart GE, Staunton KC, Buckley NE, McDyer FA, Kennedy RD, Wilson RH, Mullan PB, Harkin DP.

Breast Cancer Res Treat. 2010 Aug;122(3):721-31. doi: 10.1007/s10549-009-0565-0. Epub 2009 Oct 31.

PMID:
19882246
16.

BRCA1 and implications for response to chemotherapy in ovarian cancer.

Quinn JE, Carser JE, James CR, Kennedy RD, Harkin DP.

Gynecol Oncol. 2009 Apr;113(1):134-42. doi: 10.1016/j.ygyno.2008.12.015. Epub 2009 Jan 24. Review.

PMID:
19168207
17.

BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy.

Quinn JE, James CR, Stewart GE, Mulligan JM, White P, Chang GK, Mullan PB, Johnston PG, Wilson RH, Harkin DP.

Clin Cancer Res. 2007 Dec 15;13(24):7413-20.

18.

Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.

Hosey AM, Gorski JJ, Murray MM, Quinn JE, Chung WY, Stewart GE, James CR, Farragher SM, Mulligan JM, Scott AN, Dervan PA, Johnston PG, Couch FJ, Daly PA, Kay E, McCann A, Mullan PB, Harkin DP.

J Natl Cancer Inst. 2007 Nov 21;99(22):1683-94. Epub 2007 Nov 13.

19.

BRCA1, a potential predictive biomarker in the treatment of breast cancer.

James CR, Quinn JE, Mullan PB, Johnston PG, Harkin DP.

Oncologist. 2007 Feb;12(2):142-50. Review.

20.

The role of BRCA1 in transcriptional regulation and cell cycle control.

Mullan PB, Quinn JE, Harkin DP.

Oncogene. 2006 Sep 25;25(43):5854-63. Review.

PMID:
16998500
21.

BRCA1 and c-Myc associate to transcriptionally repress psoriasin, a DNA damage-inducible gene.

Kennedy RD, Gorski JJ, Quinn JE, Stewart GE, James CR, Moore S, Mulligan K, Emberley ED, Lioe TF, Morrison PJ, Mullan PB, Reid G, Johnston PG, Watson PH, Harkin DP.

Cancer Res. 2005 Nov 15;65(22):10265-72.

22.

Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms.

Quinn JE, Brown LG, Zhang J, Keller ET, Vessella RL, Corey E.

Prostate Cancer Prostatic Dis. 2005;8(3):253-9.

PMID:
15999121
23.

The 2,5 oligoadenylate synthetase/RNaseL pathway is a novel effector of BRCA1- and interferon-gamma-mediated apoptosis.

Mullan PB, Hosey AM, Buckley NE, Quinn JE, Kennedy RD, Johnston PG, Harkin DP.

Oncogene. 2005 Aug 18;24(35):5492-501.

PMID:
15940267
24.

Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer.

Kwak EL, Moberg KH, Wahrer DC, Quinn JE, Gilmore PM, Graham CA, Hariharan IK, Harkin DP, Haber DA, Bell DW.

Gynecol Oncol. 2005 Jul;98(1):124-8.

PMID:
15913747
25.

Osteoprotegerin in prostate cancer bone metastasis.

Corey E, Brown LG, Kiefer JA, Quinn JE, Pitts TE, Blair JM, Vessella RL.

Cancer Res. 2005 Mar 1;65(5):1710-8.

26.

The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft.

Kiefer JA, Vessella RL, Quinn JE, Odman AM, Zhang J, Keller ET, Kostenuik PJ, Dunstan CR, Corey E.

Clin Exp Metastasis. 2004;21(5):381-7.

27.

The role of BRCA1 in the cellular response to chemotherapy.

Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP.

J Natl Cancer Inst. 2004 Nov 17;96(22):1659-68. Review.

PMID:
15547178
28.

BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3.

Gilmore PM, McCabe N, Quinn JE, Kennedy RD, Gorski JJ, Andrews HN, McWilliams S, Carty M, Mullan PB, Duprex WP, Liu ET, Johnston PG, Harkin DP.

Cancer Res. 2004 Jun 15;64(12):4148-54.

29.

Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines.

Liu AY, Brubaker KD, Goo YA, Quinn JE, Kral S, Sorensen CM, Vessella RL, Belldegrun AS, Hood LE.

Prostate. 2004 Jul 1;60(2):98-108.

PMID:
15162376
30.

Characterization of C4-2 prostate cancer bone metastases and their response to castration.

Pfitzenmaier J, Quinn JE, Odman AM, Zhang J, Keller ET, Vessella RL, Corey E.

J Bone Miner Res. 2003 Oct;18(10):1882-8.

31.

BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.

Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG, Harkin DP.

Cancer Res. 2003 Oct 1;63(19):6221-8.

32.

The biology of breast carcinoma.

Kennedy RD, Quinn JE, Mullan PB, Harkin DP.

Cancer. 2003 Sep 15;98(6):1327-8; author 1328-9. No abstract available.

33.

Outcomes in EMS-transported attendees from events at a large indoor arena.

Chan SB, Quinn JE.

Prehosp Emerg Care. 2003 Jul-Sep;7(3):332-5.

PMID:
12879383
34.

Haploinsufficiency and reduced expression of genes localized to the 8p chromosomal region in human prostate tumors.

Chaib H, MacDonald JW, Vessella RL, Washburn JG, Quinn JE, Odman A, Rubin MA, Macoska JA.

Genes Chromosomes Cancer. 2003 Jul;37(3):306-13.

35.

A novel method of generating prostate cancer metastases from orthotopic implants.

Corey E, Quinn JE, Vessella RL.

Prostate. 2003 Jul 1;56(2):110-4.

PMID:
12746835
36.

LuCaP 35: a new model of prostate cancer progression to androgen independence.

Corey E, Quinn JE, Buhler KR, Nelson PS, Macoska JA, True LD, Vessella RL.

Prostate. 2003 Jun 1;55(4):239-46.

PMID:
12712403
37.

Molecular characterization of prostatic small-cell neuroendocrine carcinoma.

Clegg N, Ferguson C, True LD, Arnold H, Moorman A, Quinn JE, Vessella RL, Nelson PS.

Prostate. 2003 Apr 1;55(1):55-64.

PMID:
12640661
38.

Role played by BRCA1 in regulating the cellular response to stress.

Gilmore PM, Quinn JE, Mullan PB, Andrews HN, McCabe N, Carty M, Kennedy RD, Harkin DP.

Biochem Soc Trans. 2003 Feb;31(Pt 1):257-62. Review.

PMID:
12546697
39.

Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.

Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, Vessella RL.

Clin Cancer Res. 2003 Jan;9(1):295-306. Erratum in: Clin Cancer Res. 2003 Apr;9(4):1574-5.

40.

BRCA1: mechanisms of inactivation and implications for management of patients.

Kennedy RD, Quinn JE, Johnston PG, Harkin DP.

Lancet. 2002 Sep 28;360(9338):1007-14. Review.

PMID:
12383682
41.

BRCA1 regulates the interferon gamma-mediated apoptotic response.

Andrews HN, Mullan PB, McWilliams S, Sebelova S, Quinn JE, Gilmore PM, McCabe N, Pace A, Koller B, Johnston PG, Haber DA, Harkin DP.

J Biol Chem. 2002 Jul 19;277(29):26225-32. Epub 2002 May 13.

42.

Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells.

Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Vessella RL.

Prostate. 2002 Jun 1;52(1):20-33.

PMID:
11992617
43.

Inhibition of androgen-independent growth of prostate cancer xenografts by 17beta-estradiol.

Corey E, Quinn JE, Emond MJ, Buhler KR, Brown LG, Vessella RL.

Clin Cancer Res. 2002 Apr;8(4):1003-7.

44.

BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents.

Mullan PB, Quinn JE, Gilmore PM, McWilliams S, Andrews H, Gervin C, McCabe N, McKenna S, White P, Song YH, Maheswaran S, Liu E, Haber DA, Johnston PG, Harkin DP.

Oncogene. 2001 Sep 27;20(43):6123-31.

45.

The CWH8 gene encodes a dolichyl pyrophosphate phosphatase with a luminally oriented active site in the endoplasmic reticulum of Saccharomyces cerevisiae.

Fernandez F, Rush JS, Toke DA, Han GS, Quinn JE, Carman GM, Choi JY, Voelker DR, Aebi M, Waechter CJ.

J Biol Chem. 2001 Nov 2;276(44):41455-64. Epub 2001 Aug 14.

47.

Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo.

Melchior SW, Brown LG, Figg WD, Quinn JE, Santucci RA, Brunner J, Thüroff JW, Lange PH, Vessella RL.

Int J Oncol. 1999 Mar;14(3):501-8.

PMID:
10024683
48.

Valuing dental practice.

Gluck GM, Civelek K, Resillez F, Solden A, Quinn JE.

Compend Contin Educ Dent. 1997 Jan;18(1):50-2, 54, 56 passim.

PMID:
9161137
49.

A computer-prepared employee manual for the 21st century.

Quinn JE.

Compend Contin Educ Dent. 1995 Jun;16(6):590, 592, 594-5 passim. No abstract available.

PMID:
8620389
50.

Trends in dental computerization in Oklahoma practices.

Quinn JE.

J Okla Dent Assoc. 1994 Fall;85(2):36-42. No abstract available.

PMID:
9526231

Supplemental Content

Loading ...
Support Center